M. Hong Nguyen

Ceftazidime-Avibactam Is Superior to Other Treatment Regimens against Carbapenem-Resistant Klebsiella pneumoniae Bacteremia

Ryan K. Shields, M. Hong Nguyen, Liang Chen et al. · Antimicrobial Agents and Chemotherapy · 2017 · 487 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +13

Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne <i>bla</i> _KPC-3 Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections

Ryan K. Shields, Liang Chen, Shaoji Cheng et al. · Antimicrobial Agents and Chemotherapy · 2016 · 485 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections: Table 1.

Ryan K. Shields, Brian A. Potoski, Ghady Haidar et al. · Clinical Infectious Diseases · 2016 · 428 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides

Raymond F. Schinazi, Robert M. Lloyd, M. Hong Nguyen et al. · Antimicrobial Agents and Chemotherapy · 1993 · 367 citations

Life Sciences, Infectious Diseases, Pharmacology +14

Pneumonia and Renal Replacement Therapy Are Risk Factors for Ceftazidime-Avibactam Treatment Failures and Resistance among Patients with Carbapenem-Resistant Enterobacteriaceae Infections

Ryan K. Shields, M. Hong Nguyen, Liang Chen et al. · Antimicrobial Agents and Chemotherapy · 2018 · 286 citations · Full text

Life Sciences, Clinical Sciences, Infectious Diseases +17